Oncosec Medical (ONCS) – Hot FDA News
-
Oncosec Medical (ONCS) Reports Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab
-
Oncosec Medical (ONCS) Commences Clinical Trial KEYNOTE-695 of ImmunoPulse IL-12 in Combination with Merck's (MRK) KEYTRUDA (pembrolizumab)
-
-
Back to ONCS Stock Lookup